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Abstract 
The widespread prevalence and deleterious effects of metabolic syndrome have become a major 
public  health  challenge  as  it  is  associated  with  the  development  of  type  2  diabetes  and 
cardiovascular disease.  Lifestyle modification focusing on diet has shown promise for managing 
cardiovascular  disease  risk,  and  clinical  studies  provide  evidence  that  a  Mediterranean  diet 
supplemented  with  phytochemicals  is  a  successful  interventional  approach.    The  role  of 
phytochemicals in regulating gene expression and modulating intracellular kinase activity has 
only  recently  begun  to  be  appreciated.  Clinical  studies  investigating  the  effects  of  specific 
phytochemicals in metabolic syndrome patients have produced encouraging results, including 
normalization  of  metabolic  function,  reduction  of  cardiovascular  risk,  and  resolution  of 
metabolic syndrome.  As research advances our understanding of the evolutionary relationships 
between  plants  and  humans,  details  are  emerging  about  the  mechanisms  by  which 
phytochemicals regulate insulin signaling and inflammatory responses. This expanding field of 
research is likely to lead to novel, effective clinical approaches for combating chronic diseases 
such as metabolic syndrome. 
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Introduction 
In 1949, H.P. Himsworth at the London School of Medicine authored a paradigm-shifting article 
in the Lancet entitled “The syndrome of diabetes mellitus and its causes” [1]. He proposed that 
there was a type of diabetes that was not related to the lack of insulin secretion from beta cells of 
the pancreas, but rather to the lack of sensitivity to the insulin signal at the peripheral tissue level 
[1]. In 1984, G.M. Reaven at Stanford School of Medicine described a comparable disruption of 
insulin action upon insulin sensitive tissues that was associated with risk to both diabetes and 
cardiovascular disease, which he later termed Syndrome X [2]. Reaven described this syndrome 
as  a  diet  sensitive  condition  [2].  It  was  subsequently  referred  to  as  “metabolic  syndrome,” 
characterized by hyperinsulinemia and insulin resistance. The constellation of factors that define 
metabolic syndrome are described in Figure 1.  
 
Figure 1. Constellation of factors contributing to the metabolic syndrome according to the diagnostic 
guidelines by Grundy et al. [17]. Abdominal obesity is referred to as a waist circumference of ≥102 cm 
(40 in) in men and ≥88cm (35 in) in women. Atherogenic dyslipidemia refers to triglycerides of ≥1.7 
mmol/L (150 mg/dL) or pharmaceutical therapy for hypertriglyceridemia, as well as low HDL, defined as 
<1.03 mmol/L (40 mg/dL) in men or <1.3 mmol/L (50 mg/dL) in women or pharmaceutical therapy for 
low HDL. Elevated fasting blood glucose refers to levels ≥5.55 mmol/L (100 mg/dL) or pharmaceutical 
treatment for elevated glucose. Elevated blood pressure is ≥130 mm Hg systolic blood pressure or ≥85 
mm Hg diastolic blood pressure or pharmaceutical therapy for hypertension. Meeting any 3 of 5 criteria Functional Foods in Health and Disease, 2011, 2:1-12                                     Page 3 of 12                       
constitutes diagnosis of metabolic syndrome. Finally, increased thrombosis and inflammation are recent 
additions to the metabolic syndrome cascade. Reproduced with permission from [36]. 
 
The  2010  report  of  the  WHO  Expert  Consultation  Committee  defined  metabolic 
syndrome as a pre-morbid condition rather than a clinical diagnosis, and they suggested that it 
should  exclude  individuals  with  established  diabetes  or  known  cardiovascular  disease  [3]. 
Grundy described the “metabolic syndrome pandemic” as a metabolic disturbance that is related 
to a multiplex of several risk correlates of metabolic origin, and which affects as much as 24% of 
the adult population in the United States and is growing rapidly in prevalence throughout the 
world [4]. Metabolic syndrome has been linked to dyslipidemia, hypertension, hyperglycemia, 
and a prothrombotic and proinflammatory state [5]. Controversy has persisted as to whether 
metabolic syndrome is caused by obesity or merely correlates with central obesity. Recently a 
joint  statement  of  the  International  Diabetes  Task  Force  on  Epidemiology  and  Prevention, 
National Heart, Lung and Blood Institute, American Heart Association (AHA), World Health 
Federation, International Atherosclerosis Society, and the International Association for the Study 
of  Obesity  concluded  that  increase  in  girth  (i.e.  waist  circumference)  was  not  a  primary 
biomarker  required  for  the  definition  of  metabolic  syndrome  [6].  Nevertheless,  metabolic 
syndrome with and without central obesity has been associated not only with increased risk for 
type 2 diabetes and cardiovascular disease, but also with polycystic ovarian syndrome, erectile 
dysfunction, sleep apnea, non-alcoholic fatty liver disease, hypertension, breast and colon cancer, 
and cognitive impairment related to a variant form of Alzheimer’s disease [7-11]. 
 
Relationship between metabolic syndrome and diet 
Based upon this evolution of consideration since 1984, the current state of understanding is that 
metabolic  syndrome  represents  the  consequence  of  a  complex  interplay  of  genes  and 
environment resulting in metabolic disturbances and increased risk for many chronic diseases. 
Specific  dietary  factors  have  been  identified  as  key  environmental  agents  that  compromise 
metabolic function [12]. Considerable discussion has focused on determining the preferential 
dietary pattern for the prevention and management of metabolic syndrome. A food plan that 
incorporates  a  low  glycemic  load  has  been  found  to  improve  insulin  signaling  and  reduce 
metabolic risk factors [13]. Replacement of refined carbohydrates with protein in the diet was 
found to be advantageous for the management of metabolic syndrome [14], as was a reduction in 
saturated fat and an increase in omega-3 oils [15, 16]. 
The  dietary  plan  that  is  emerging  as  the  superior  approach  for  the  management  of 
metabolic  syndrome  is  the  Mediterranean  diet  [17].  A  systematic  review  of  thirty-five 
intervention  studies  concluded  that  this  dietary  approach  demonstrated  favorable  effects  on 
lipoprotein levels, endothelial function, insulin sensitivity, and cardiovascular function, including 
a reduction in carotid artery intima-media thickness [18]. Others reported that the Mediterranean 
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The role of the Mediterranean diet in managing conditions of insulin resistance is also consistent 
with the demonstrated value of this dietary approach for the management of newly diagnosed 
type 2 diabetes [20, 21]. In the Healthy Aging Longitudinal Study in Europe (HALE study) of 
individuals 70 to 90 years of age, consumption of a Mediterranean diet and healthful lifestyle 
was associated with a more than 50% lower rate of all-cause mortality and reduction in both 
diabetes  and  cardiovascular  diseases,  compared  to  an  age-matched  control  group  of  people 
maintaining their normal dietary and lifestyle patterns [22]. 
 
The role of specific phytochemicals as a component of the Mediterranean diet 
on metabolic syndrome 
The Mediterranean diet is low in refined carbohydrates, sugars, and saturated and trans fats, and 
high  in  fiber,  monounsaturated  and  polyunsaturated  oils,  and  phytochemicals.  Schiltz  et  al. 
emphasized the diversity of phytochemical-rich foods in the Mediterranean diet as a primary 
factor  for  its  success  in  managing  conditions  associated  with  insulin  resistance  [23].  In  a 
companion article, “Metabolic Syndrome and the Components of the Mediterranean Diet”, Dr. 
Maria  Luz  Fernandez  presents  evidence  that  consumption  of  a  Mediterranean-style  diet  is 
associated with reduced risk for heart disease and type 2 diabetes, and illustrates how several 
components  of  the  Mediterranean  diet  have  a  positive  impact  on  symptoms  of  metabolic 
syndrome. 
Studies of the Mediterranean diet, such as in the recent trial conducted by Camargo et al., 
illustrate  the  importance  of  gene-diet  interactions  in  disease  modification  [24].  Specifically, 
certain phytochemicals can differentially modulate the postprandial gene expression profile in 
people with metabolic syndrome and help to normalize disturbed metabolic functions associated 
with this condition.  
Most recently, it has been suggested that phytochemicals produced in environmentally 
stressed  plants  have  beneficial  effects  on  the  reduction  of  metabolic  stress  for  animals  that 
consume  them.  This  relationship  between  humans  and  stress  compounds  in  plants  has  been 
termed “xenohormesis” [25]. Between 5,000 and 10,000 phytochemicals have been identified, 
and the average daily intake of these phytochemicals from a standard diet is estimated at 1.5 
grams  [26].  Individuals  consuming  the  Mediterranean  diet  ingest  significantly  more 
phytochemicals than people consuming the standard American diet [27], and the additive and 
synergistic effects of phytochemicals provide desirable health benefits beyond basic nutrition in 
reducing the risk for chronic disease [28]. Recent food recall studies have found that 8 out of 10 
Americans have a “phytonutrient gap,” such that their daily diet lacks between 69% and 88% of 
important  xenohormetic  phytochemicals,  which  could  potentially  result  in  adverse  metabolic 
outcomes [29].  
Recently Babish et al. reported results from a screening of phytochemicals from 206 
foods and spices for activity on components of insulin signaling pathways [30]. The authors 
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significant insulin sensitizing bioactivity. These observations have been supported by additional 
studies.  For  example,  Gymnema  sylvestre  extract,  which  has  been  used  for  the  treatment  of 
diabetes in India for centuries, possesses anti-diabetic phytochemicals [31]. The prickly pear 
cactus (Opuntia ficus-indica), which has been used in traditional medicine for diabetes by native 
Central and North Americans, contains insulin sensitizing phytochemicals [32]. Ethanolic extract 
of licorice (Glycyrrhiza uralensis Fisher) was reported to contain phytochemicals that bind to 
peroxisome  proliferator-activated  receptor  gamma  and  reduce  the  metabolic  disturbances  in 
diabetic mice [33]. Minich and Bland examined reports on the clinical efficacy and safety of 
crucifer-derived phytochemicals in regulating steroid hormone metabolism and speculated on 
how  they  might  modulate  risk  to  chronic  disease  [34].  Recently  a  placebo  controlled  study 
evaluating the activities  of  various phytochemicals  from  green tea (epigallocatechin  gallate), 
grapes  (resveratrol),  tomato  (lutein),  and  soy  oil  (tocopherol)  was  conducted  in  overweight 
individuals  [35].  The  authors  observed  that  supplementation  with  the  phytochemical  extract 
resulted  in  the  reduction  of  risk  factors  associated  with  inflammation  and  oxidative  and 
metabolic  stress  [35].  Further,  compounds  in  many  berry  species  have  been  identified  as 
antioxidants or anti-diabetics. An expanded discussion on the bioactive properties of berries may 
be  found  in  the  companion  article  by  Dr.  Mary  Ann  Lila,  “Impact  of  Bioflavonoids  from 
Berryfruits on Biomarkers of Metabolic Syndrome”. 
 
Putative mechanism of action of phytochemicals in metabolic syndrome 
In a review by Minich and Bland, the authors suggested that due to the complexity of metabolic 
syndrome, tailored dietary approaches including the evaluation of phytochemical content would 
be important [36]. This is an area that deserves much more research attention. Lukaczer et al. 
conducted an intervention trial in participants with metabolic syndrome who were randomized to 
either  the  AHA  Step  1  diet  or  a  low-glycemic-load  diet  supplemented  with  soy  protein 
(containing  isoflavones)  and  phytosterols  [37].  They  found  significant  improvements  in 
cardiovascular risk factors in the group that received the phytochemical-enriched diet [37]. Izzo 
et al. reported that individuals with metabolic syndrome had a reduction in central obesity and 
improvements in lipid profile, diastolic blood pressure, and Framingham Risk Scores after eight 
weeks of phytochemical supplementation [38].  
Mechanistic studies have found that specific phytochemicals regulate insulin signaling 
through  complex  nutrigenomic  and  intracellular  signaling  networks  (reviewed  in  [36]).  For 
example, Barnes reported that plant polyphenols influence gene expression, transcription, and 
protein  expression  and  function,  preventing  metabolic  disturbance  in  cellular  systems  [39]. 
Chung  et  al.  reported  that  dietary  polyphenols  activate  the  Sirtuin  1  gene,  which  regulates 
metabolism, stress resistance, cellular survival, cellular senescence/aging, inflammation-immune 
function, endothelial functions, and circadian rhythms [40].  
Further, there is an increasing body of literature indicating that specific phytochemicals 
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patients with chronic diseases. For instance, flavonoids have been found to bind to Akt/protein 
kinase B (PKB), Fyn, Janus kinase 1 (JAK1), mitogen-activated protein kinase kinase 4 (MKK4) 
and phosphoinositide-3-kinase (PI3K) [41]. Adipocytes isolated from insulin resistant patients 
exhibit impaired insulin signaling, reduced insulin receptor substrate-1 (IRS-1) gene and protein 
expression, and dysfunctional insulin-stimulated PI3K and Akt/PKB signaling [42]. Minich et al. 
reported  that  phytochemical  extracts  from  Humulus  lupulus  (hops)  and  Acacia  nilotica 
selectively  modulated  kinases  within  the  insulin  signaling  cascade  and  produced  favorable 
insulin sensitizing effects in 3T3-L1 mouse adipocytes and in diabetic db/db mice [43]. Tan et al. 
demonstrated that an extract from bitter melon (Momordica charantia) had agonist activity for 
AMP-activated protein kinase (AMPK) in 3T3-L1 adipocytes and enhanced glucose disposal in 
insulin-resistant mice [44]. A schematic representation for the putative role of phytochemicals in 
insulin signaling is illustrated in Figure 2.  
 
Figure 2. General diagrammatic representation of the insulin-signaling cascade. Insulin is the substrate 
that  leads  to  a  cascade  of  cellular  reactions  responsible  for  glucose  and  lipid  metabolism.  Insulin 
stimulates the insulin receptor (IR) tyrosine kinase, leading to the tyrosine phosphorylation of the insulin 
receptor  substrate  (IRS)  family  of  proteins.  Activated  IRS  then  displays  binding  sites  for  numerous 
signaling partners such as phosphatidylinositol-3 kinase (PI3K), a key player in insulin function through 
the  activation  of  the  Akt/protein  kinase  B  (PKB).  When  stimulated,  Akt/PKB  promotes  glycogen 
synthesis via upregulation of the glycogen synthase enzyme which occurs with inhibition of glycogen Functional Foods in Health and Disease, 2011, 2:1-12                                     Page 7 of 12                       
synthase  kinase  (GSK)-3.  Additionally,  insulin  activates  glucose  uptake  via  a  family  of  glucose 
transporters (GLUT).  Through negative feedback, PI3K, Akt/PKB, and GSK-3 and can result in serine 
phosphorylation of IRS, and subsequent inactivation. Activation of G-protein coupled receptors can lead 
to activation of protein kinase C (PKC). Excessive stress through inflammatory mediators such as tumor 
necrosis factor-α (TNF- α) or through metabolic overflow of lipid from adipose tissue could also impact 
the insulin signaling cascade. Reproduced with permission from [36]. 
 
There are undoubtedly a number of different mechanisms by which phytochemicals from 
different  foods and spices  can modulate cellular signaling and metabolic processes. What  is 
emerging from this work is that a complex diet rich in minimally processed vegetables, fruits, 
grains and legumes supplies an array of phytochemicals that can have a xenohormetic influence 
on metabolic syndrome.  
 
Clinical intervention with phytochemicals in patients with metabolic 
syndrome 
Lerman  et  al.  conducted  a  randomized,  twelve-week,  dietary  intervention  trial  in  metabolic 
syndrome patients [45]. The control arm received a modified Mediterranean-style low-glycemic-
load  food  plan;  the  intervention  arm  received  the  same  food  plan  but  also  received 
supplementation with phytosterols, soy protein including isoflavones, hops plant derived rho iso-
alpha  acids,  and  proanthocyanidins  from  Acacia  nilotica.  Results  of  this  trial  were  very 
encouraging as both arms experienced improvement in several cardiovascular risk variables [45]. 
Remarkably, the arm that received additional phytochemicals had  a much superior outcome, 
including a greater percentage of subjects experiencing net resolution of metabolic syndrome 
[45]. In a retrospective sub-analysis of participants with higher cardiovascular disease risk (i.e. 
those with metabolic syndrome plus LDL levels in excess of 160 mg/dl), Lerman et al. found that 
the additional phytochemical supplementation was needed in order to adequately reduce multiple 
biomarkers associated with cardiovascular disease in this high-risk population [46]. Details of 
these studies are presented in Dr. Robert Lerman’s companion article, “A Nutritional Approach 
to the Metabolic Syndrome”. 
Other conditions closely associated with insulin resistance have also been investigated. 
For example, in a study of patients with nonalcoholic steatohepatitis, Sanyal et al. found that 
patients  receiving  a  supplemental  dose  of  800-IU  of  alpha-tocopherol  (vitamin  E)  showed 
significant improvement in liver histology after 96 weeks compared to those receiving a placebo 
[47]. Two studies of myo-inositol, a phytochemical found in many foods including barley, the 
fruit Cucurbita ficifolia, soy, and buckwheat, demonstrated that it has insulin sensitizing effects 
and reduces dense LDL particles while increasing serum plasmalogens in people with metabolic 
syndrome, as well as improving polycystic ovary syndrome in women with dysfunctional insulin 
signaling [48, 49]. 
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Conclusions  
The trajectory of current research on the role of phytochemicals in regulating insulin signaling 
and metabolic syndrome suggests that this will continue to be a fertile area for basic and clinical 
scientific  investigation.  Dwyer  recently  pointed  out  that  phytochemicals  and  other  bioactive 
substances  in  food  have  potential  use  for  safe  and  effective  prevention  and  management  of 
chronic diseases [50]. The newly recognized roles of specific phytochemicals as modulators of 
kinase-dependent  intracellular  signal  transduction  and  also  as  activators  of  enzymes  such  as 
Sirtuin 1 open the door for robust mechanistic investigations.  
It  is  tantalizing  to  contemplate  the  potential  evolutionary  significance  of  mechanistic 
associations between adaptive response processes in plants and animals through phytochemical-
dependent  functions.  Xenohormetic  relationships  between  dietary  phytochemicals  and 
consumers of traditional diets may have been evolutionarily established for the conservation of 
vital cellular processes. Investigation into the mechanisms underlying such relationships may 
reveal new methods for targeting chronic diseases such as metabolic syndrome. 
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